Top
Security
Historical Summary
Company Profile
Documentation
Notices
Relevant Facts until 10/05/2020
Significant participations
Financial Reports
Historic Info.
Trades
Corporate Actions
Gallery

AB-BIOTICS D2011-NOVIEMBRE

Trading sesion

21/11/2011 Close

0.0110

Last price

0.06 mill. €

Capitalisation

-26.67

Dif.(%)

% Year

Miguel Ángel Bonachera - Sergi Audivert

CEOs

Excluded 23/11/2011

Print Web

Last Trade

Date

21/11/2011

Hour

Last

0.0110

Ref.

0.0150

Dif.(%)

-26.67

Volume (Shares)

12,348

Turnover (€x1000)

0.14

Go to 5-year chart

Security

Security name

AB-BIOTICS D2011-NOVIEMBRE

Ticker

ABB.D

ISIN

ES0609659901

NIF

A-63497473

Shares Admitted

5.470.446

Nominal

Capital Admitted

Trading

Continuo

Liquidity Provider

Registered Advisor

Auditor

KPMG AUDITORES, S.L

Address

AV/ DE LA TORRE BLANCA 57, 08173 SANT CUGAT DEL VALLÉS

Contact

info@ab-biotics.com

Other Issuer shares

Historical Summary

	2011 until 22/11
Capital Admitted (thousands of euros)	n/a
Shares (x 1,000)	5,470
Period Close Price (euros)	0.0110
Period Last Price (euros)	0.0110
Period High Price (euros)	0.1020
Period Low Price (euros)	0.0110
Capitalisation (thousands of euros)	60
Volume (thousands of shares)	16
Turnover (thousands of euros)	0

Company Profile

AB-BIOTICS is a Spanish company founded in Barcelona in 2004, leading Biotechnology and whose activity is diversified into two business areas based on the research, development, protection and distribution of biotech own unique solutions, with a mission to improve the health and wellbeing of people.

AB-BIOTICS has an innovative philosophy and has a know-how that allows itself to develop cutting-edge products that provide high added value to market. The AB-BIOTICS projects offer the pharmaceutical and food products greater efficiency and help to improve the health of people while helping reduce health care costs.

AB-BIOTICS is organized into two business areas:

NEUROFARMAGEN (AB-GENOTYPING): focuses on the development of genetic analysis to develop pharmacogenetic studies (the way in which patients will respond to different treatments and drugs, based on their genetic inheritance) which provide more information to doctors about the most effective treatments and appropriate dose for each patient (personalized medicine).

AB-BIOTICS FUNCTIONAL INGREDIENTS: probiotics and other nutraceuticals are developed for the pharmaceutical industry and food industries. These functional ingredients are useful for the prevention and treatment of a wide range of illnesses, from cardiovascular to infantile colic, among others.

AB-BIOTICS has a multidisciplinary team led by counselors Miquel Angel Bonachera and Sergi Audivert. The organization combines the talents of young, dynamic and highly qualified professionals with extensive international experience and success in business and biotechnology.

Source: issuer.

Web

Documentation

02/11/2011 17:40 AB-BIOTICS, S.A. Ampliación de capital - Noviembre 2011 (3 MB)

13/07/2011 16:48 AB-BIOTICS, S.A. Ampliación de capital -Julio 2011 (1 MB)

31/05/2011 17:16 AB-BIOTICS, S.A. Documento Informativo de Incorporación (11 MB)

See more...See less...

Notices

12/05/2014 16:32 AB-BIOTICS Notice: Non periodical results information AB-BIOTICS Hecho Relevante: Información sobre Plan de Negocio (48 KB)

Relevant Facts until 10/05/2020

04/10/2019 21:10 AB-BIOTICS Relevant Fact: Others on corporate information Publicación del procedimiento sobre la oferta de adquisición de acciones en el marco de la exclusión de cotización. (751 KB)

04/10/2019 18:23 AB-BIOTICS Relevant Fact: Announcements and agreements of shareholders general meetings Acuerdos de la Junta General Extraordinaria. Aprobación de la exclusión de negociación. (109 KB)

26/09/2019 19:39 AB-BIOTICS Relevant Fact: Announcements and agreements of shareholders general meetings Traducción de documentación relacionada con la convocatoria de Junta General Extraordinaria (2 MB)

19/09/2019 22:18 AB-BIOTICS Relevant Fact: Announcements and agreements of shareholders general meetings Orden del día y propuestas de acuerdos de la JGE de Accionistas tras el complemento de convocatoria (439 KB)

17/09/2019 12:45 AB-BIOTICS Relevant Fact: Announcements and agreements of shareholders general meetings Complemento de Convocatoria de Junta General Extraordinaria de Accionistas (185 KB)Related to Relevant Fact 03/09/2019 23:50

10/09/2019 18:51 AB-BIOTICS Relevant Fact: Announcements and agreements of shareholders general meetings Traducción de documentación relacionada con la convocatoria de Junta General Extraordinaria (147 KB)Related to Relevant Fact 03/09/2019 23:50

06/09/2019 10:12 AB-BIOTICS Relevant Fact: Operations carried out by management Operaciones de directivos (174 KB)

03/09/2019 23:50 AB-BIOTICS Relevant Fact: Announcements and agreements of shareholders general meetings Convocatoria de Junta General. Propuesta de exclusión de negociación (9 MB)

29/08/2019 12:07 AB-BIOTICS Relevant Fact: Operations carried out by management Operaciones de directivos (176 KB)

23/08/2019 16:17 AB-BIOTICS Relevant Fact: Public offer of shares Resultado de la oferta pública voluntaria de adquisición realizada por KANEKA (47 KB)Related to Relevant Fact 24/07/2019 22:41

06/08/2019 09:34 AB-BIOTICS Relevant Fact: Public offer of shares Sobre acuerdos del Consejo de Administración en relación con la oferta realizada por Kaneka: Fairness Opinion emitida por Ernst & Young Servicios Corporativos, S.L. en castellano. (2 MB)Related to Relevant Fact 24/07/2019 22:41

26/07/2019 17:58 AB-BIOTICS Relevant Fact: Public offer of shares Traducción del hecho relevante relativo a decisiones del Consejo de Aministración sobre la oferta de Kaneka (2 MB)Related to Relevant Fact 24/07/2019 22:41

24/07/2019 22:41 AB-BIOTICS Relevant Fact: Public offer of shares Acuerdos del Consejo de Administración en relación con la oferta realizada por Kaneka (2 MB)

11/07/2019 22:14 AB-BIOTICS Relevant Fact: Public offer of shares Acuerdos del Consejo de Administración en relacion con la oferta realizada por Kaneka (89 KB)Related to Relevant Fact 09/07/2019 23:24

10/07/2019 18:49 AB-BIOTICS Relevant Fact: Public offer of shares Versión inglesa del anuncio de oferta publica voluntaria de adquisición de acciones por parte de Kaneka (2 MB)Related to Relevant Fact 09/07/2019 23:24

09/07/2019 23:24 AB-BIOTICS Relevant Fact: Public offer of shares Anuncio de Oferta Pública Voluntaria de Adquisición de acciones por parte de Kaneka. (2 MB)

02/07/2019 12:46 AB-BIOTICS Relevant Fact: Significant participations Participaciones significativas a 30 de junio de 2019 (70 KB)

01/07/2019 16:30 AB-BIOTICS Relevant Fact: Announcemnt of public presentation and meetings Aclaración sobre la presentación del Foro MedCap en relación con la ausencia de previsiones futuras (89 KB)Related to Relevant Fact 29/05/2019 09:38

14/06/2019 19:59 AB-BIOTICS Relevant Fact: Operations carried out by management Operaciones de directivos (253 KB)

29/05/2019 09:38 AB-BIOTICS Relevant Fact: Announcemnt of public presentation and meetings Presentación foro MedCap 2019 (3 MB)

26/04/2019 13:53 AB-BIOTICS Relevant Fact: Announcements and agreements of shareholders general meetings Acuerdos de la Junta General Ordinaria y Extraordinaria. (123 KB)Related to Relevant Fact 20/03/2019 14:20

20/03/2019 14:20 AB-BIOTICS Relevant Fact: Announcements and agreements of shareholders general meetings Convocatoria de Junta General Ordinaria y Extraordinaria de Accionistas (144 KB)

20/03/2019 14:19 AB-BIOTICS Relevant Fact: Periodical financial information Información anual 2018 en inglés (2 MB)

20/03/2019 14:17 AB-BIOTICS Relevant Fact: Shareholders agreements affecting voting rigths Pactos Parasociales (320 KB)

25/02/2019 09:34 AB-BIOTICS Relevant Fact: Composition of the Board of Directors Cambios en el Consejo de Administración (70 KB)

09/01/2019 18:27 AB-BIOTICS Relevant Fact: Significant participations Participaciones significativas a 31/12/2018. (83 KB)

See more...See less...

Significant participations

10/01/2018 15:21 AB-BIOTICS Relevant Fact: Significant participations Participaciones significativas a 31 de Diciembre de 2017. (431 KB)

See more...See less...

09/01/2013 10:30 AB-BIOTICS, S.A. Relevant Fact: Significant participations AB-BIOTICS, S.A. Hecho Relevante: Participaciones significativas (154 KB)

See more...See less...

Financial Reports

Photo Gallery

To obtain detailed information or information in other formats, please contact BME Market Data at marketdata@grupobme.es or visit the website www.bmemarketdata.es.

The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties for a fee, it is required a prior and express permission from BME Market Data. Please contact us at marketdata@grupobme.es.